Scholarlink

Introduction <p>There is a strong recommendation for the use of tranexamic acid in pertrochanteric fractures in the elderly; however, there is controversy about which doses and routes of administration are optimal. We aimed to determine whether intravenous administration, together with local application, offers a synergistic effect in reducing blood loss.</p> Methods <p>We conducted a double-blind, randomized, placebo-controlled clinical trial comparing elderly patients (&gt; 65&#xa0;years) with pertrochanteric fractures, distributed into two groups:</p> <p>Treatment (n = 43): Received intravenous tranexamic acid (adjusted to the standard dose) and a local application of 3&#xa0;g at the end of surgery.</p> <p>Control (n = 47): Received the same intravenous dose of tranexamic acid and a local placebo (3&#xa0;g saline solution).</p> <p>The main variables were differences in blood loss measured by hemoglobin, hematocrit, and transfusion requirements.</p> Results <p>Perioperative hemoglobin losses did not show significant differences (p = 0.738), nor did hematocrit (p = 0.488) or perioperative transfusion requirements (p = 0.283). Analysis according to fracture characteristics and treatment (short nail vs. long nail without open reduction vs. long nail with open reduction) showed similar, non-significant results.</p> Discussion <p>Tranexamic acid in this patient group is beneficial on its own, but we did not observe a synergistic effect when combining intravenous and local administration. Our recommendation is single systemic use, given its simpler administration, lower dosage requirements, and equivalent therapeutic effect.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Does the Synergistic Systemic and Local Application of Tranexamic Acid Reduce Blood Loss in Patients with Pertrochanteric Hip Fractures in the Elderly? Clinical Trial in a Tertiary Hospital Centre

  • 期刊论文

  • 发表日期：

    2025年11月30日

查看全文
  • Jaime Flores Gallardo,
  • Coral Sánchez Pérez,
  • Francisco Javier Vaquero Martín

摘要

Introduction

There is a strong recommendation for the use of tranexamic acid in pertrochanteric fractures in the elderly; however, there is controversy about which doses and routes of administration are optimal. We aimed to determine whether intravenous administration, together with local application, offers a synergistic effect in reducing blood loss.

Methods

We conducted a double-blind, randomized, placebo-controlled clinical trial comparing elderly patients (> 65 years) with pertrochanteric fractures, distributed into two groups:

Treatment (n = 43): Received intravenous tranexamic acid (adjusted to the standard dose) and a local application of 3 g at the end of surgery.

Control (n = 47): Received the same intravenous dose of tranexamic acid and a local placebo (3 g saline solution).

The main variables were differences in blood loss measured by hemoglobin, hematocrit, and transfusion requirements.

Results

Perioperative hemoglobin losses did not show significant differences (p = 0.738), nor did hematocrit (p = 0.488) or perioperative transfusion requirements (p = 0.283). Analysis according to fracture characteristics and treatment (short nail vs. long nail without open reduction vs. long nail with open reduction) showed similar, non-significant results.

Discussion

Tranexamic acid in this patient group is beneficial on its own, but we did not observe a synergistic effect when combining intravenous and local administration. Our recommendation is single systemic use, given its simpler administration, lower dosage requirements, and equivalent therapeutic effect.